Equashield a leading provider of Closed System Transfer Devices (CSTDs) for hazardous drugs, announced that it will be l...
China based CMAB Biopharma Inc. (CMAB), a full-service contract development and manufacturing organization (CDMO) provid...
Nabriva Therapeutics, a clinical stage biopharmaceutical company engaged in the research and development of novel anti-i...
Fresenius Medical Care, the world's largest provider of dialysis products and services, has announced a new partnership ...
Hua Medicine, a clinical-stage drug development company developing novel therapies for the treatment of Type 2 diabetes,...
Singlera Genomics, a non-invasive genetic diagnostics company that focuses on early-stage cancer detection, has succ...
Boehringer Ingelheim (BI) has teamed up with two China animal health companies, Beijing KangMu Omni-Hones...
Allergan plc announces the launch of Ozurdex® (dexamethasone intravitreal implant 0.7 mg) in China for the treatment...
WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for bio...
Inovio Pharmaceuticals, today announced that it has inked an agreement providing ApolloBio with the exclusive right to d...
Akonni Biosystems Inc. and Chinese in vitro diagnostics company, Righton, recently announced a commercial agreement that...
Dova Pharmaceuticals, Inc. has entered into an agreement through its wholly owned subsidiary, AkaRx, Inc., granting Shan...
Loncar Investments, LLC has recently announced the launch of the Loncar China BioPharma Index (LCHINA), the world&r...
PierianDx, the leading genomics technology company that enables precision medicine programs and molecular testing for he...
Chinese scientists have developed an artificial heart using rocket technology and it is currently undergoing testing aft...
Taiwan-based United Biopharma (UBP) has recently partnered with GE Healthcare Life Sciences to build a biologics facilit...
A consortium of leading global investors including Temasek and Sequoia Capital China has joined the $90-millio...
Shanghai based diabetes drug developer, Hua Medicine has picked Hong Kong over the U.S. for its initial public offe...
